arrow
O

Ozren Jakšić

division of haematology
H指数:25
被引数:2,980

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal changes in left atrial function during chronic ibrutinib therapy: a prospective observational study

慢性伊布替尼治疗期间左心房功能的纵向变化:一项前瞻性观察研究

2026-09-010
OA
Common genomic and transcriptomic signatures in Richter transformation highlight druggable vulnerabilities and guide drug repurposing strategies

Richter转化的共同基因组学和转录组学特征突显可用药脆弱性并指导药物重定位策略

Leukemia
IF13.4
2026-04-140
OAAI
Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europe

针对慢性淋巴细胞白血病中布托替尼酪氨酸激酶抑制剂的 cardiovascular toxicities 的处理:中欧和东欧血液学家的实用建议

2025-11-070
OAAI
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病中中枢神经系统受累:ERIC(欧洲慢性淋巴细胞白血病研究倡议)国际回顾性研究

2025-10-280
OAAI
Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases

Obinutuzumab联合替代苯丁酸氮芥方案在慢性淋巴细胞白血病的一线治疗中: 克罗地亚血液病合作组织KroHem的一项研究

2024-12-200
OAAI
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病患者的治疗策略和治疗顺序: 欧洲CLL研究计划ERIC的国际研究

2024-09-170
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (vol 52, pg 1125, 2024)

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查结果 (第52卷,1125页,2024页)

2024-05-210
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查的结果

2024-02-224
OAAI
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

通过新型冠状病毒肺炎大流行,多发性骨髓瘤和SARS-COV-2感染的生存率: epicovideha注册表的结果

2023-12-049
OAAI
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CLL历史上的其他恶性肿瘤: ERIC进行的一项国际多中心研究,欧洲CLL研究倡议,和谐

2023-11-016
OAAI
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

慢性淋巴细胞白血病患者新型冠状病毒肺炎和COVID后病情的演变: 欧洲CLL研究计划ERIC的一项研究

2023-09-2911
OAAI
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

BTK和PLCG2在接受依鲁替尼治疗的CLL复发患者的3分之1中保持未突变

2023-06-1638
OAAI
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

新型冠状病毒肺炎血液系统恶性肿瘤患者的尼马曲韦/利托那韦: EPICOVIDEHA登记处的报告

2023-04-0123
OAAI
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry
2023-03-114
OAAI
B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
2022-10-0413
OAAI